The FDA is proposing two studies to examine how well consumers and health care professionals can identify false or misleading information in prescription drug promotions. The studies will involve mock promotional websites for fictitious prescription drugs targeting chronic pain and obesity. The first study will focus on the level of deception involved. In other words, are consumers and providers more apt to identify the deception when a promotion contains numerous misleading claims? The second study will look at the effect of the type of violations involved.